Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Genmab A/S (GMAB)

36.61   -0.72 (-1.93%) 10-01 09:17
Open: 36.37 Pre. Close: 37.33
High: 36.92 Low: 36.08
Volume: 795,011 Market Cap: 23,694M

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 37.737 - 37.889 37.889 - 38.045
Low: 36.567 - 36.725 36.725 - 36.887
Close: 37.111 - 37.385 37.385 - 37.668

Technical analysis

as of: 2020-09-30 4:42:07 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 45.40     One year: 53.03
Support: Support1: 35.87    Support2: 34.01
Resistance: Resistance1: 38.87    Resistance2: 45.40
Pivot: 36.77
Moving Average: MA(5): 36.28     MA(20): 36.59
MA(100): 33.96     MA(250): 26.94
MACD: MACD(12,26): 0.13     Signal(9): 0.18
Stochastic oscillator: %K(14,3): 55.80     %D(3): 43.56
RSI: RSI(14): 53.65
52-week: High: 38.87  Low: 16.24  Change(%): 97.9
Average Vol(K): 3-Month: 61795  10-Days: 77959

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
GMAB has closed below upper band by 36.8%. Bollinger Bands are 12.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Tue, 29 Sep 2020
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - GlobeNewswire

Tue, 29 Sep 2020
Capital Increase in Genmab as a Result of Employee Warrant Exercise -

Thu, 24 Sep 2020
Genmab A/S (NASDAQ:GMAB) Finding Zero Support - The Oracle Dispatch

Wed, 23 Sep 2020
Moderate Buy Genmab A/S [GMAB] Stock Before Shares Hit Major Turbulence -

Tue, 22 Sep 2020
Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen - GlobeNewswire

Mon, 21 Sep 2020
Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020 - GlobeNewswire

Financial Analysis

Growth n/a
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability n/a
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency n/a
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Neutral Discounted cash flow: Neutral
Return on Assets: Neutral Price to Earnings: Neutral
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 652
Shares Float (M) 645
% Held by Insiders
% Held by Institutions 4.00
Shares Short (K) 970
Shares Short P. Month (K) 654

Stock Financials

EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin 54.68
Operating Margin
Return on Assets (ttm) 29.9
Return on Equity (ttm) 43.3
Qtrly Rev. Growth 604.3
Gross Profit (p.s.) 8.231
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth 3874.10
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio
PEG Ratio 2.35
Price to Book value
Price to Sales
Price to Cash Flow

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.